Current Status of Cognition and Clinical Practice of Refractory Cancer Pain in Shanghai: A Questionnaire Survey
DOI: https://doi.org/10.2147/jpr.s452605
IF: 2.8319
2024-04-09
Journal of Pain Research
Abstract:Jing Zhang, 1, 2 Ke Ma, 3 Jun Yan, 4 Pingsheng Pan, 5 Jiangshan Yin, 6 Fuqing Lin, 7 Hui Chen, 8 Weiwei Zhao, 1, 2 Menglei Chen, 1, 2 Zhe Zhang, 1, 2 Minghui Liu, 1, 2 Xiaoli Gu, 1, 2 Xinghe Liao, 1, 2 Chenyue Zhang, 1, 2 Wenwu Cheng 1, 2 1 Department of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China; 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; 3 Department of Pain Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; 4 Department of Oncology, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, People's Republic of China; 5 Department of Oncology, Fangta Hospital of Traditional Chinese Medicine in Songjiang District, Shanghai, People's Republic of China; 6 Department of Oncology, Fudan University Shanghai Cancer Center, Minhang Branch, Shanghai, People's Republic of China; 7 Department of Anaesthesiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China; 8 Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, People's Republic of China Correspondence: Wenwu Cheng, Email Purpose: This study aimed to assess the current status of clinical practice of refractory cancer pain (RCP) among a sample of physicians specializing in cancer pain management in Shanghai. Methods: From 2019 to 2021, a questionnaire survey was conducted among physicians engaged in diagnosis and treatment of cancer pain through the questionnaire WJX network platform in Shanghai, China. Results: A total of 238 responses participated in the survey. This survey reports physicians' understanding and incidence rate of breakthrough cancer pain (BTCP). The choice of analgesics and satisfaction of analgesic effect were investigated. We also investigated doctors' knowledge of the diagnostic criteria for RCP and their tendency to choose analgesics. Oral immediate-release morphine and intravenous or subcutaneous morphine injection have been the common treatment approach for transient cancer pain exacerbations. The main barriers to pain management are lack of standardized treatment methods for RCP, lack of knowledge related to RCP, and single drug dosage form. Doctors believe the most necessary measures to improve the current situation of poor cancer pain control include improving medical staff's understanding and treatment techniques for RCP, updating treatment techniques and methods, and improving the configuration of drug types in medical institutions. Clinicians expect to improve understanding and treatment techniques through systematic training. Conclusion: Despite multiple available analgesic measures, the treatment of RCP remains challenging. Improving the understanding of medical staff towards RCP, improving treatment techniques, and increasing the accessibility of multiple drug types are important ways to improve the satisfaction of cancer pain management in the future. Keywords: refractory cancer pain, breakthrough cancer pain, pain management, opioid drugs According to the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO), there were 19.29 million new cancer cases worldwide in 2020, with 4.57 million new cases in China. 1 More than half of cancer patients experience moderate-to-severe pain, and part of them felt that their cancer pain treatment is inadequate. Refractory cancer pain (RCP) has been described as persistent pain related to cancer or its treatment. RCP is difficult to respond to standard treatment with opioid drugs and co-analgesics. 2 However, there is no standard definition recognized by international experts. The lack of international consensus on the definition of RCP in clinical practice may contribute to failures in pain management. According to reports, 10–20% of cancer patients suffer from RCP. RCP has become a thorny problem faced by both doctors and patients. 3 RCP usually persists longer than three months and is associated with significant physical, psychosocial, and social implications. Poor pain control can result in increased healthcare costs, extended hospital stays, increased patient suffering, and decreased patient satisfaction. The reasons for poor -Abstract Truncated-
clinical neurology